Loading…
← CockpitCompetitor Analysis › MOBI Mobia Medical, Inc.Open in the cockpit ↗

Mobia Medical, Inc.MOBICompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum leader 91
Mkt cap
$434M
US dollars, full cap
Free float
38%
of shares outstanding
$/day
$2.46M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.5%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$13.03
1D+3.3%
1W-3.3%
1M+44.1%
3M+19.0%
6M+2.2%
YTDn/a
1Yn/a
ATR %7.4%
52w lowhigh14.8% off high

What Mobia Medical does

Employees: 167

Mobia Medical at a glance

Size Mobia Medical (MOBI) is a United States Health Care company (Medical Specialties) with a market value of $434M, the 2779th largest of 3,085 United States companies the cockpit tracks. Shares closed at $13.03 on 18 Nov 2026.

Performance Over six months the shares gained 2.2%, against -21.1% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue grew 104.8% over the last twelve months (peer median +1.4%); the operating margin is -144.7% (peer median 6.1%).

Valuation It trades at 8.8× enterprise value to sales against a peer median of 3.9× (3rd most expensive of 19).

Short interest Short interest is 3.0% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026MOBI 104Peer median 81
Six months, rebased to 100: Mobia Medical against the median of its 20 peers (local-currency closes).

Mobia Medical financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenuen/a$32.0M$15.6M
Revenue growth—+105%—
Gross profitn/a$25.8M$12.3M
EBITDAn/a-$46.2M-$24.1M
Net incomen/a-$46.5M-$24.6M
Free cash flown/a-$46.1M-$24.4M
Capital expendituren/a$364,411$40,848
Total debt$8.37M$8.44M$7.72M

Quarterly statements and history in the cockpit →

Mobia Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%0%+20%+40%688026SI300110REG1V1763300515CU63010976039870020169877468530300289MDXG688358688133603309ANGOMOBI6-month return →1-month return →
Up and to the right = strong over both horizons. Mobia Medical is the large dot.

Fundamentals: revenue growth against valuation

0%+250%+500%+750%+1,000%0×200×400×688026SI9877468530MOBIRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Mobia Medical is the large dot.

Mobia Medical competitors and peer comparison

How Mobia Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Mobia Medical against its 20 peers (data as of 18 Nov 2026)
MeasureMOBIPeer medianRank in peer set
1-month return+44.1%-9.3%highest of 21
6-month return+2.2%-21.1%4th highest of 21
Distance from 52-week high-14.8%-44.8%highest of 21
Revenue growth (TTM)+104.8%+1.4%2nd highest of 20
Operating margin-144.7%6.1%2nd lowest of 20
EV / Sales8.8×3.9×3rd most expensive of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Mobia Medical MOBIUnited States$434M+2%+105%-145%8.8×n/an/a
Guangzhou Jet Bio-Filtration 688026.SSChina$436M+39%+5%11%4.8×20.6%+2.2%
Shoulder Innovations SIUnited States$432M+39%+55%-54%5.5×n/an/a
Huaren Pharmaceutical 300110.SZChina$440M-16%-3%6%3.3×5.8%+0.3%
Revenio REG1V.HEFinland$428M-34%+44%10%4.0×18.5%+12.4%
China Isotope & Radiation 1763.HKHong Kong$428M-41%-5%13%n/an/an/a
Hunan Sundy Science and Technology 300515.SZChina$425M-16%+10%27%3.5×-0.1%+15.6%
Clarity Pharmaceuticals CU6.AXAustralia$444M-33%n/an/an/an/an/a
Ningbo Tianyi Medical Appliance 301097.SZChina$418M-22%+46%8%4.4×n/an/a
Shanghai Kindly Enterprises Development 603987.SSChina$452M-12%0%10%1.5×-1.0%-2.8%
Guangdong Shirongzhaoye 002016.SZChina$453M-26%-31%3%3.8×21.5%-11.7%
Jenscare Scientific 9877.HKHong Kong$415M-32%+993%-106%17.8×n/an/a
PROTEINA 468530.KSSouth Korea$460M+5%-59%-1,178%410.3×n/an/a
Beijing Leadman Biochemistry 300289.SZChina$460M-9%+46%1%8.2×36.0%-6.9%
MiMedx MDXGUnited States$464M-16%-23%-8%1.1×10.9%+11.0%
Chison Medical Technologies 688358.SSChina$406M-27%-1%19%3.9×9.6%+5.6%
Eiken Chemical 4549.TJapan$466M-20%+4%6%1.6×n/an/a
Shanghai Titan Scientific 688133.SSChina$403M-26%+1%-6%1.4×n/an/a
WELL LEAD MEDICAL 603309.SSChina$473M-22%+1%15%2.0×-5.9%+7.7%
Guanhao Biotech 300238.SZChina$397M-26%-12%3%7.1×n/an/a
AngioDynamics ANGOUnited States$476M-4%+8%-6%1.4×n/an/a

Questions

Which companies are Mobia Medical's closest peers?
The cockpit's peer set: Guangzhou Jet Bio-Filtration (688026.SS), Shoulder Innovations (SI), Huaren Pharmaceutical (300110.SZ), Revenio (REG1V.HE), China Isotope & Radiation (1763.HK), Hunan Sundy Science and Technology (300515.SZ), Clarity Pharmaceuticals (CU6.AX), Ningbo Tianyi Medical Appliance (301097.SZ).
Is Mobia Medical expensive compared with its peers?
On ev / sales it trades at 8.8× against a peer median of 3.9×, 3rd most expensive of 19 in its peer set.
How has Mobia Medical stock performed?
Over six months to 18 Nov 2026 the shares returned +2.2% against -21.1% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.